Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2019-07-01 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东股份减持计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a shareholding reduction plan by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number and percentage of shares to be reduced, the methods and timing of the reduction, and related regulatory compliance. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal disclosure of a planned shareholding change by major shareholders, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short (1970 characters), and it is not an announcement of a report publication or a certification. Therefore, the appropriate classification is MRQ with high confidence.
2019-07-01 Chinese
关于限售股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from 福安药业 (Fuan Pharmaceutical Group Co., Ltd.) regarding the lifting of restrictions on certain shares and their subsequent listing for circulation. It details the number of shares being unlocked, the shareholders involved, the dates of share circulation, and the changes in shareholding structure before and after the unlocking. The document includes specific data on share quantities, percentages of total share capital, and shareholder commitments related to the restricted shares. There is no financial performance data, earnings information, or management discussion. The document is an official notice about share circulation and unlocking of restricted shares, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories. The document length is under 5,000 characters, but it contains substantive information about share capital changes, not just a report publication announcement. Therefore, the best classification is Share Issue/Capital Change (SHA).
2019-06-25 Chinese
东莞证券股份有限公司关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易部分限售股份解除限售之核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the lifting of restrictions on certain restricted shares related to a major asset restructuring transaction by the company 福安药业（集团）股份有限公司. It includes specifics about share issuance, lock-up periods, shareholder commitments, shareholding changes, and compliance with regulatory requirements. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a specialized report related to a capital market transaction and share restriction lifting, which fits best under Capital/Financing Update (CAP) as it deals with share issuance, restricted shares, and capital structure changes.
2019-06-25 Chinese
关于收到注射用头孢米诺钠一致性评价受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (811 characters) from a company about receiving a regulatory acceptance notice from the National Medical Products Administration regarding a drug consistency evaluation application. It is an official announcement of a regulatory event related to product approval, not a financial report, management change, or shareholder meeting material. It does not contain financial data, earnings, or detailed report content. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2019-06-25 Chinese
关于支付定金的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 福安药业 (Fuan Pharmaceutical Group Co., Ltd.) regarding the payment of a deposit (定金) related to a cooperation framework agreement signed on April 28, 2019. It details the payment amount, the escrow account setup, and the regulatory measures to ensure the deposit's safety and compliance. The document also mentions ongoing due diligence and the uncertainty of signing a formal cooperation agreement. The document length is 1852 characters, which is relatively short and primarily serves as an announcement of a transaction event rather than a detailed financial report or management discussion. There are no financial statements, earnings data, or management analysis included. The content fits best with a Capital/Financing Update (CAP) as it relates to a financing-related transaction (payment of a deposit for a potential business cooperation). It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or a report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2019-06-05 Chinese
第四届董事会第四次会议决议公告（现场表决和通讯表决相结合方式）
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding a specific meeting held on May 31, 2019. It details the attendance, voting procedure, and the approval of a particular agenda item related to a subsidiary's agreement. There is no financial data, no mention of annual or quarterly reports, no audit information, and no regulatory certifications. The content focuses on board decisions and meeting resolutions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2019-06-02 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.